Rapamune and Glomerulonephritis proliferative - a phase IV clinical study of FDA data

Summary:

Glomerulonephritis proliferative is reported as a side effect among people who take Rapamune (sirolimus), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Cyclosporine,.

The phase IV clinical study analyzes which people have Glomerulonephritis proliferative when taking Rapamune. It is created by eHealthMe based on reports of 13,732 people who have side effects when taking Rapamune from the FDA, and is updated regularly.

What is Rapamune?

Rapamune has active ingredients of sirolimus. It is often used in kidney transplant. eHealthMe is studying from 13,848 Rapamune users. Check the latest studies of Rapamune.

What is Glomerulonephritis proliferative?

Glomerulonephritis proliferative (a disorder of the glomeruli (glomerulonephritis), or small blood vessels in the kidneys) is found to be associated with 55 drugs and 174 conditions by eHealthMe. Check the latest studies of Glomerulonephritis proliferative.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

13,732 people reported to have side effects when taking Rapamune.
Among them, 27 people (0.2%) have Glomerulonephritis proliferative.

Could Rapamune cause Glomerulonephritis proliferative?

Among these 27 people:

How long have people been on Rapamune when they have Glomerulonephritis proliferative? *

What is the gender of people who have Glomerulonephritis proliferative when taking Rapamune? *

female: 55.56 %
male: 44.44 %

What is the age of people who have Glomerulonephritis proliferative when taking Rapamune? *

What are other drugs people take besides Rapamune? *

What are other side effects people have besides Glomerulonephritis proliferative? *

Kidney Transplant Rejection: 4 people, 14.81%
Acute Kidney Failure: 4 people, 14.81%
Thrombotic Microangiopathy (a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury): 4 people, 14.81%
Drug Toxicity: 4 people, 14.81%
Nausea And Vomiting: 3 people, 11.11%
Disease Recurrence: 3 people, 11.11%
Haematuria (presence of blood in urine): 2 people, 7.41%
Nephropathy (damage to or disease of a kidney): 2 people, 7.41%
Nephrosclerosis (hardening of the kidney due to renovascular disease): 2 people, 7.41%
Nephrotic Syndrome (kidney disease with proteinuria, hypoalbuminemia, and oedema): 2 people, 7.41%

* Approximation only. Some reports may have incomplete information.

Do you take Rapamune and have Glomerulonephritis proliferative?

- Check whether Glomerulonephritis proliferative is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rapamune:

Rapamune (13,848 reports)

Browse all side effects of Rapamune:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Glomerulonephritis proliferative:

Glomerulonephritis proliferative (55 drugs)

Browse all the conditions that are associated with Glomerulonephritis proliferative:

Glomerulonephritis proliferative (174 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sirolimus (the active ingredients of Rapamune) and Rapamune (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.